These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 24567430)

  • 21. Efficacy and safety of crizotinib among Chinese EML4-ALK-positive, advanced-stage non-small cell lung cancer patients.
    Cao Y; Xiao G; Qiu X; Ye S; Lin T
    PLoS One; 2014; 9(12):e114008. PubMed ID: 25501361
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
    Rodig SJ; Shapiro GI
    Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers.
    Atherly AJ; Camidge DR
    Br J Cancer; 2012 Mar; 106(6):1100-6. PubMed ID: 22374459
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economic analysis of ALK testing and crizotinib therapy for advanced non-small-cell lung cancer.
    Lu S; Zhang J; Ye M; Wang B; Wu B
    Pharmacogenomics; 2016 Jun; 17(9):985-94. PubMed ID: 27266545
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced nonsquamous non-small cell lung cancer.
    Klein R; Muehlenbein C; Liepa AM; Babineaux S; Wielage R; Schwartzberg L
    J Thorac Oncol; 2009 Nov; 4(11):1404-14. PubMed ID: 19786904
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted therapies in non-small-cell lung cancer management: no cost-effective strategies?
    Chouaid C; Borget I; Vergnenegre A
    J Clin Oncol; 2014 Nov; 32(31):3577. PubMed ID: 25199755
    [No Abstract]   [Full Text] [Related]  

  • 27. Treatment of ALK-positive non-small cell lung cancer.
    Bang YJ
    Arch Pathol Lab Med; 2012 Oct; 136(10):1201-4. PubMed ID: 23020724
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
    Brown T; Boland A; Bagust A; Oyee J; Hockenhull J; Dundar Y; Dickson R; Ramani VS; Proudlove C
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):71-9. PubMed ID: 21047494
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Isolated central nervous system progression on Crizotinib: an Achilles heel of non-small cell lung cancer with EML4-ALK translocation?
    Chun SG; Choe KS; Iyengar P; Yordy JS; Timmerman RD
    Cancer Biol Ther; 2012 Dec; 13(14):1376-83. PubMed ID: 22986231
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Crizotinib.
    Heigener DF; Reck M
    Recent Results Cancer Res; 2014; 201():197-205. PubMed ID: 24756793
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting ALK in patients with advanced non small cell lung cancer: biology, diagnostic and therapeutic options.
    Lazzari C; Spitaleri G; Catania C; Barberis M; Noberasco C; Santarpia M; Delmonte A; Toffalorio F; Conforti F; De Pas TM
    Crit Rev Oncol Hematol; 2014 Mar; 89(3):358-65. PubMed ID: 24156959
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preselection based on clinical characteristics in German non-small-cell lung cancer patients screened for EML4-ALK translocation.
    Tufman AL; Edelmann M; Gamarra F; Reu S; Borgmeier A; Schrödl K; Zauber R; Müller-Lisse U; Huber RM
    J Thorac Oncol; 2014 Jan; 9(1):109-13. PubMed ID: 24346098
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting stemness is an effective strategy to control EML4-ALK+ non-small cell lung cancer cells.
    Oh SJ; Noh KH; Lee YH; Hong SO; Song KH; Lee HJ; Kim S; Kim TM; Jeon JH; Seo JH; Kim DW; Kim TW
    Oncotarget; 2015 Nov; 6(37):40255-67. PubMed ID: 26517679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Favorable response to crizotinib in three patients with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion-type oncogene-positive non-small cell lung cancer.
    Kijima T; Takeuchi K; Tetsumoto S; Shimada K; Takahashi R; Hirata H; Nagatomo I; Hoshino S; Takeda Y; Kida H; Goya S; Tachibana I; Kawase I
    Cancer Sci; 2011 Aug; 102(8):1602-4. PubMed ID: 21767331
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China.
    Guan H; Sheng Y; Guo W; Han S; Shi L
    Adv Ther; 2019 May; 36(5):1114-1125. PubMed ID: 30900201
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer.
    Georgieva M; da Silveira Nogueira Lima JP; Aguiar P; de Lima Lopes G; Haaland B
    Lung Cancer; 2018 Oct; 124():248-254. PubMed ID: 30268469
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic and therapeutic issues for patients with advanced non‑small cell lung cancer harboring anaplastic lymphoma kinase rearrangement: European vs. US perspective (review).
    Di Maio M; De Marinis F; Hirsch FR; Gridelli C
    Int J Oncol; 2014 Aug; 45(2):509-15. PubMed ID: 24859689
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer.
    Greenhalgh J; McLeod C; Bagust A; Boland A; Fleeman N; Dundar Y; Oyee J; Dickson R; Davis H; Green J; McKenna E; Pearson M
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):33-9. PubMed ID: 21047489
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intact or broken-apart RNA: an alternative concept for ALK fusion screening in non-small cell lung cancer (NSCLC).
    Kotoula V; Bobos M; Vassilakopoulou M; Tsolaki E; Chrisafi S; Psyrri A; Lazaridis G; Papadopoulou K; Efstratiou I; Michail-Strantzia C; Debelenko LV; Kosmidis P; Fountzilas G
    Appl Immunohistochem Mol Morphol; 2015 Jan; 23(1):60-70. PubMed ID: 25153496
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genotyping lung cancer is an investment in the future.
    Azzoli CG; Engelman J; Fidias P; Gainor JF; Heist RS; Lamont EB; Lennes IT; Rosovsky RP; Sequist LV; Shaw AT; Temel JS
    J Clin Oncol; 2014 Nov; 32(31):3576-7. PubMed ID: 25199750
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.